ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,317.59
-0.26%
Dow Jones
39,069.59
0.01%
Gold vs US Dollar
2,334.20
0.00%
Brent Oil
81.965
0.00%
Bitcoin
69,108.91
-0.23%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) News

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VNDA
DateTimeSourceHeadlineSymbolCompany
24/05/202421:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202421:46PR Newswire (US)Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its ShareholdersNASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202421:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
24/05/202421:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
21/05/202421:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
21/05/202421:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
21/05/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
21/05/202421:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VNDAVanda Pharmaceuticals Inc
20/05/202422:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
15/05/202413:45PR Newswire (US)Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion SicknessNASDAQ:VNDAVanda Pharmaceuticals Inc
13/05/202421:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VNDAVanda Pharmaceuticals Inc
09/05/202422:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VNDAVanda Pharmaceuticals Inc
09/05/202412:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202421:01PR Newswire (US)Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
07/05/202421:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
07/05/202416:16PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
30/04/202421:30PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
25/04/202413:05GlobeNewswire Inc.Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsNASDAQ:VNDAVanda Pharmaceuticals Inc
23/04/202400:13PR Newswire (US)Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202415:21PR Newswire (US)Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202414:02PR Newswire (US)Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
03/04/202415:25AllPennyStocks.comBiotech Catches Major Premarket Bid Following FDA ApprovalNASDAQ:VNDAVanda Pharmaceuticals Inc
02/04/202423:10PR Newswire (US)Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I DisorderNASDAQ:VNDAVanda Pharmaceuticals Inc
07/03/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VNDA

Your Recent History

LSE
BOO
Boohoo
LSE
BARC
Barclays
LSE
VAST
Vast Resources
LSE
IQE
Iqe
LSE
PAF
Pan African Resources
LSE
LLOY
Lloyds Banking
LSE
THUS
Thus
LSE
SPEC
Inspecs
LSE
CUSN
Cornish Metals
LSE
AAZ
Anglo Asian Mining
LSE
BVC
Batm Advanced Communicat...
LSE
SRSP
Sirius Petroleum
LSE
THG
Thg
LSE
TERN
Tern
LSE
SCE
Surface Transforms
LSE
GDR
Genedrive
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved